Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
CONCLUSIONS: An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.PMID:37343187 | DOI:10.1093/ajh/hpad055 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - June 21, 2023 Category: Cardiology Authors: Hongyi Wang Yang Xi Yuanyuan Chen Luyan Wang Fan Yang Xining Lu Ningling Sun Source Type: research
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
CONCLUSIONS: An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.PMID:37343187 | DOI:10.1093/ajh/hpad055 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - June 21, 2023 Category: Cardiology Authors: Hongyi Wang Yang Xi Yuanyuan Chen Luyan Wang Fan Yang Xining Lu Ningling Sun Source Type: research
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
CONCLUSIONS: An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.PMID:37343187 | DOI:10.1093/ajh/hpad055 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - June 21, 2023 Category: Cardiology Authors: Hongyi Wang Yang Xi Yuanyuan Chen Luyan Wang Fan Yang Xining Lu Ningling Sun Source Type: research
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
CONCLUSIONS: An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.PMID:37343187 | DOI:10.1093/ajh/hpad055 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - June 21, 2023 Category: Cardiology Authors: Hongyi Wang Yang Xi Yuanyuan Chen Luyan Wang Fan Yang Xining Lu Ningling Sun Source Type: research
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
CONCLUSIONS: An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.PMID:37343187 | DOI:10.1093/ajh/hpad055 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - June 21, 2023 Category: Cardiology Authors: Hongyi Wang Yang Xi Yuanyuan Chen Luyan Wang Fan Yang Xining Lu Ningling Sun Source Type: research
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension
CONCLUSIONS: An allisartan-isoproxil-based antihypertensive regimen can effectively control BP in patients with mild-to-moderate EH.PMID:37343187 | DOI:10.1093/ajh/hpad055 (Source: American Journal of Hypertension)
Source: American Journal of Hypertension - June 21, 2023 Category: Cardiology Authors: Hongyi Wang Yang Xi Yuanyuan Chen Luyan Wang Fan Yang Xining Lu Ningling Sun Source Type: research
Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy
CONCLUSION: This real-world analysis showed that switching to a triple single-pill combination could offer an opportunity to improve adherence to antihypertensive treatment in real-life clinical practice.PMID:36829102 | DOI:10.1007/s12325-023-02451-y (Source: Adv Data)
Source: Adv Data - February 24, 2023 Category: Epidemiology Authors: Claudio Borghi Pathiyil Balagopalan Jayagopal Alexandra Konradi Luiz Aparecido Bortolotto Luca Degli Esposti Valentina Perrone Jacques R Snyman Source Type: research
Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy
ConclusionThis real-world analysis showed that switching to a triple single-pill combination could offer an opportunity to improve adherence to antihypertensive treatment in real-life clinical practice. (Source: Advances in Therapy)
Source: Advances in Therapy - February 24, 2023 Category: Drugs & Pharmacology Source Type: research
Incidence of severe hypokalaemia in patients taking indapamide
ConclusionsIn this large population-based study with 147,319 person-years of follow-up, severe hypokalaemia requiring hospitalisation was uncommon among hypertensive patients on indapamide. The risk is higher in women and in the initial weeks and months after starting therapy. The use of the sustained-release formulation reduces the risk. We conclude that using indapamide to treat hypertension is safe, even in the elderly, especially if the sustained-release formulation is used and electrolytes are monitored periodically. (Source: Internal and Emergency Medicine)
Source: Internal and Emergency Medicine - January 30, 2023 Category: Emergency Medicine Source Type: research
The impact of different diuretics on regression of myocardial reperfusion injury in spontaneously hypertensive rats
Mol Cell Biochem. 2022 Dec 27. doi: 10.1007/s11010-022-04622-x. Online ahead of print.ABSTRACTThe study's objective was to ascertain the results of sub-chronic therapy of various diuretics on the ischemia/reperfusion dysfunction of the heart in hypertensive rats by a global ischemia in an isolated rat heart model. The research included 40 spontaneously hypertensive male rats (Wistar Kyoto strain, body mass 250 ± 30 g, 8 weeks old) grouped into four groups. The animals were treated for 4 weeks with 10 mg/kg of hydrochlorothiazide, indapamide, or spironolactone per os. After a period of sub-chronic treatment, we analyzed he...
Source: Molecular and Cellular Biochemistry - December 26, 2022 Category: Biochemistry Authors: Nevena Dragasevic Maja Savic Katarina Mihajlovic Vladimir Zivkovic Marijana Andjic Nevena Draginic Nebojsa Zdravkovic Sergey Bolevich Stefani Bolevich Vladimir Jakovljevic Tamara Nikolic Turnic Source Type: research
EE207 Real-World Analysis of Adherence, Outcomes and Healthcare Costs of Patients Under Quadruple Combination of Antihypertensives in Italy
this real-world analysis aimed to evaluate adherence, outcomes and direct healthcare costs in hypertensive patients treated with 4 antihypertensive drugs belonging to ACE-inhibitor/calcium-antagonist/diuretic/beta-blocker(ACE-I/CCB/DIU/BB) classes or with perindopril/amlodipine/indapamide/bisoprolol(PER/AML/IND/BIS), in Italy. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: L Degli Esposti, S Brouwers, G Desideri, V Perrone, K Narkiewicz, G Mancia Source Type: research
EE478 Do Triple Single-Pill Combinations Make a Difference in Treatment Adherence, Outcomes and Healthcare Resource Utilization in Hypertension? A Real-World Analysis of Patients on Perindopril/Amlodipine/Indapamide in Italy
A real-world analysis was performed to compare adherence, outcomes and healthcare costs in hypertensive patients prescribed perindopril/amlodipine/indapamide (PER/AML/IND) as single-pill vs free combination, in Italy. (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: J Snyman, P Balagopalan Jayagopal, A Konradi, LA Bortolotto, L Degli Esposti, V Perrone, C Borghi Source Type: research
Impact of the COVID-19 pandemic on cardiovascular heart disease medication use: time-series analysis of England's prescription data during the COVID-19 pandemic (January 2019 to October 2020)
CONCLUSION: A concerning decline in uptake of CVD therapies for chronic heart disease was observed. Accessible screening and treatment alongside financial relief on prescription levies are needed. A video abstract is (4 min 51 s) available: https://bit.ly/39gvEHi.PMID:36420815 | DOI:10.1177/17539447221137170 (Source: Adv Data)
Source: Adv Data - November 24, 2022 Category: Epidemiology Authors: Ravina Barrett James Hodgkinson Source Type: research
Molecules, Vol. 27, Pages 5134: Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2
In this study, a dataset containing 2115-FDA-approved drug molecules is virtually screened for potential arginase binding using molecular docking against several ARG1 and ARG2 structures. The potential arginase ligands are classified into three categories: (1) Non-selective, (2) ARG1 selective, and (3) ARG2 selective. The evaluated potential arginase ligands are then compared with their clinical use. Remarkably, half of the top 30 potential drugs are used clinically to lower blood pressure and treat cancer, infection, kidney disease, and Parkinson’s disease thus partially validating our virtual screen. Most n...
Source: Molecules - August 12, 2022 Category: Chemistry Authors: Trishna Saha Detroja Abraham O. Samson Tags: Article Source Type: research
Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors
CONCLUSIONS: Continuation of angiotensin-converting enzyme inhibitor-based therapy consistently decreased the subsequent risk of clinical outcomes, including cardiovascular and kidney outcomes and death, regardless of short-term changes in serum potassium.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), NCT00145925.PMID:35896277 | DOI:10.2215/CJN.00180122 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 27, 2022 Category: Urology & Nephrology Authors: Toshiaki Ohkuma Katie Harris Mark Cooper Diederick E Grobbee Pavel Hamet Stephen Harrap Giuseppe Mancia Michel Marre Anushka Patel Anthony Rodgers Bryan Williams Mark Woodward John Chalmers ADVANCE Collaborative Group Source Type: research
